Brigham Buhler: The Peptide Safety Data Reveals 75,000+ Patients With Zero Adverse Events |TUH #182

Gary Brecka emphasized that peptides are not drugs; they are analogs or sequences of amino acids that cause the body to secrete its own growth hormone, regulate cortisol, improve circulation, etc. Because they are building blocks of proteins, the body can break them down and eliminate waste without toxic burden. He has used them extensively in his functional medicine practice and, like Brigham Buhler's network, reports zero adverse events. The recent FDA ban, they argue, was based not on evidence of harm but on an absence of industry-style phase III trials—a standard they consider inappropriate for naturally occurring signaling molecules. They advocate for reopening access under physician guidance, now that the new administration appears receptive.

Gary Brecka and Brigham Buhler agreed that GLP-1 drugs are a legitimate tool but that prescribing them without diet, lifestyle, and nutrition is 'like brushing your teeth while eating Oreos.' They stressed that the patient must understand the medication is a bridge to sustainable habits, not a permanent fix. The conversation also highlighted how the FDA's removal of the compounding exemption, based on inflated claims that shortages were resolved, threatens to yank affordable access, leaving millions without a tool they rely on. Their recommendation is therefore layered: use the tool, but back it with real lifestyle reform, and advocate for policy that keeps it accessible.

Gary Brecka mentioned that his practice is already using large language models to tie together blood work, wearables, and body metrics. They are combining this with early cancer screening tests that detect 200 cancers at stage zero. He highlighted that groups like special forces operators and firefighters, who face disproportionate cancer risk from chemical exposures, are ideal candidates for this proactive screening. Brigham added that this 'proactive, predictive, personalized' approach is a pillar of driving healthspan and that the convergence of big data and AI is making it feasible at scale. This protocol represents a departure from annual physicals that only check a few static markers.

Gary Brecka brought up this screening as an example of the kind of proactive, predictive medicine now available. He noted that his practice is already running it, and he connected it to the MAHA movement's focus on preventing chronic disease. He argued that with the military and firefighters facing disproportionate cancer rates, large-scale prescreening should be a no-brainer. While he didn't name the lab on air, the conversation underscored the paradigm shift from reactive disease treatment to proactive detection and prevention.

Gary Brecka used PRP as an example of a widely accepted, documented therapy that works by the same principle he values in peptides: helping the body do its job better. He contrasted this with synthetic drugs that the body doesn't recognize. PRP is a precedent where a 'natural' modality gained acceptance because the evidence for safety and efficacy became overwhelming, despite initial skepticism. He sees peptides following the same trajectory.

Brigham Buhler dismantled the long-standing FDA objection to stem cells by explaining that the fear—MSCs differentiating into malignant tissues—has been disproven. He aligned MSCs with peptides in their mechanism: they give the body the signals and materials to heal itself. This is a major shift in narrative, turning a 'dangerous unknown' into a 'natural signaling tool.' The discussion occurred in the context of the MAHA administration's openness to revisiting banned therapies, so they are optimistic that this updated understanding will translate into reformed regulations.

Brigham Buhler described how his organization (Ways2Well) compiled real-world data from over 75,000 patients using peptides like BPC-157, TB-500, and thymosin alpha. Not a single adverse event was reported. He personally presented this information to FDA officials under the new administration, along with court testimonies showing that pharmaceutical companies had misled the FDA about GLP-1 shortages to justify removing compounding exemptions. The meeting was described as a learning session for FDA staff, who took extensive notes. Gary Brecka echoed the same experience from his own functional medicine practice, stating he has never seen an adverse event. They argue that with this kind of good-faith data, the FDA could be empowered to reopen access. The safety profile of peptides is framed as astronomically better than conventional drugs, with lower risk and high efficacy. This directly challenges the prior decision made in an information vacuum.

Brigham Buhler drew attention to the timeline: the FDA bans peptides, then Merck and other large pharmaceutical companies immediately start filing patents on those same peptide sequences. This suggests the ban may not have been purely about safety but about creating market exclusivity for deep-pocketed players who can afford the lengthy and expensive new drug approval process. Gary Brecka reinforces that these peptides had been helping patients for over a decade with minimal side effects. The implication is that the true safety data was never the issue; rather, it was an information vacuum filled by well-resourced lobbyists. The new administration's willingness to meet with independent clinicians and data holders is presented as the antidote to this regulatory capture.

Brigham revealed that his team called over 30,000 pharmacies monthly for 12 months and found that fewer than 6% of GLP-1 prescriptions could be filled, directly contradicting the claim that the shortage was over. He provided this data to the FDA in a meeting, along with court testimonies from pharmaceutical companies in Texas where, under oath, they admitted they had never actually met the supply volumes they reported to the FDA. This led to a decision that forced patients to pay $1,250 per month instead of $150, with many left without medication. This case illustrates the broader pattern of the FDA making decisions in a closed-door setting based on bad intel from industry. Now, with public visibility from podcasters and figures like RFK Jr., that concealment is harder to maintain.

Gary Brecka described seeing a demonstration where an AI model was asked: 'If you expose this cell to this compound in this media, what will happen?' The AI assembled information from tens of thousands of metaanalyses, clinical trials, and biological data points—handling 700 trillion independent variables—and predicted the result with exact accuracy. When the wet-lab experiment was run side-by-side, it took three years to arrive at the identical outcome. This opens the possibility of running fully randomized clinical trials in silico, dramatically accelerating the development of therapies including peptide-based treatments. Brecka ties this to the broader opportunity of using AI to analyze blood work, DEXA scans, V02 max, and wearable data to predict all-cause mortality and catch diseases at stage zero.

Brigham Buhler explained that the original FDA concern—that MSCs could become a tendon or a cancer cell—has been invalidated by newer research. Contemporary science shows that MSCs sourced from umbilical cord tissue are not capable of differentiation in vivo; instead, they operate as short-lived signaling cells. They secrete cytokines, exosomes, and extracellular vesicles, and they transfer healthy mitochondria to failing cells, essentially acting like peptides in giving the body the raw signals and materials to heal itself, then they are cleared. This mechanism aligns with the philosophy they advocate: harnessing the body's innate repair systems rather than introducing synthetic, unnatural compounds. The outdated dogma, similar to the testosterone-cancer myth, still influences policy. The hope is that the new administration will update regulatory frameworks based on this evidence.

Brigham Buhler reached out to Secretary Kennedy and his chief of staff to offer a briefing for the FDA on peptides, GLP-1s, stem cells, and other regenerative modalities. In the meeting, he found the officials in a learning mode, taking copious notes. He had to correct a statement that there was 'no clinical need for peptides' by pointing out insulin is a peptide. The leader of HHS, RFK Jr., had already publicly declared on social media that the war on these modalities was over. Gary Brecka reinforced that the administration seems open to considering good-faith data, and the closed-door, pharma-captured model of decision-making may be ending. Both expressed optimism that this could usher in a 'golden age' of preventive and regenerative care, where Americans can access safe modalities to not just treat disease but to thrive.